Lifelong Health: Long-Term Monitoring and Complications

Because D-mannose is so effective at stopping diarrhea and stabilizing blood sugar, it is easy to assume that a child who looks healthy on the outside is completely healthy on the inside. However, MPI-CDG (CDG-Ib) is a complex condition that requires lifelong vigilance. Even when a child is thriving and their primary symptoms have vanished, certain complications can develop quietly over many years. Long-term management is about “looking beneath the surface” to catch and manage these silent changes before they become serious ^[1][2].

The Challenge of “Silent” Liver Progression

The liver is one of the primary organs affected by MPI-CDG. While D-mannose treatment significantly improves liver function for most children, it does not always stop the progression of liver disease entirely ^[2].

A critical fact for parents to understand is that routine liver blood tests can be misleading. In several documented cases, children with MPI-CDG developed worsening liver scarring (fibrosis) and increased pressure in the liver’s veins (portal hypertension) even while their transaminases (AST and ALT) and albumin levels remained perfectly normal ^[1]. If a care team relies only on blood work, they may miss the early signs of liver stress.

Monitoring the Liver and Spleen

To truly understand liver health in MPI-CDG, doctors must use imaging and specialized measurements. Surveillance intervals and escalation to additional testing should be set by a hepatologist familiar with your child:

• Abdominal Ultrasound with Doppler: This is used to look at the size and texture of the liver and to check the direction and speed of blood flow in the portal vein.
• Splenomegaly (Enlarged Spleen): An enlarging spleen is often the first “silent” sign of portal hypertension. When blood cannot flow easily through a scarred liver, it backs up into the spleen, causing it to grow ^[1][3].
• Elastography (FibroScan): This non-invasive test measures “liver stiffness.” A stiffer liver often indicates higher levels of fibrosis ^[1]. (Note that these tests have limitations and do not directly measure portal pressure).
• Platelet Counts: A dropping platelet count in blood tests can be another indirect sign that the spleen is becoming overactive due to liver pressure ^[2][4], though falling platelets alone do not establish portal hypertension.

GI Bleeding Risk: Severe portal hypertension can lead to enlarged veins that may cause dangerous bleeding. Seek emergency care immediately for vomiting blood, black/tarry stools, or sudden massive abdominal swelling.

Coagulation and Blood Clotting Surveillance

Even on successful D-mannose therapy, the balance of proteins that control blood clotting can remain delicate. Many children with MPI-CDG have low levels of natural anticoagulant proteins produced by the liver, such as Antithrombin, Protein C, and Protein S, as well as other procoagulant proteins ^[5][3].

This creates a complex state where patients face both bleeding and clotting risks. Routine clotting tests (like PT/INR) may appear normal or ‘thin,’ but this does not eliminate the risk of a blood clot. Long-term monitoring of a “coagulation profile” is essential, especially:

• Before Surgery or Procedures: Any planned surgery requires a detailed review of clotting factors to prevent both excessive bleeding and dangerous blood clots ^[5].
• During Major Illness: Fever or dehydration can shift the body’s clotting balance, making a child more vulnerable to thrombosis (blood clots) ^[2][6].
• Central Lines: If your child requires a semi-permanent IV line (like a PICC line or port), they must be monitored closely, as these devices can increase the risk of a clot in children with altered coagulation ^[6].

Kidney Health and Long-Term Function

While the liver and digestive tract are the main focus in early childhood, research into adults with MPI-CDG has highlighted the need to watch the kidneys as well. Over decades, some patients have shown a gradual decline in renal function (kidney function) ^[2]. While this is not guaranteed for every patient, long-term surveillance should include:

• Blood Pressure Monitoring: High blood pressure can be an early sign of kidney stress.
• Glomerular Filtration Rate (eGFR): A blood test that measures how well the kidneys are filtering waste.
• Urinalysis: Checking for protein in the urine, which can indicate that the kidney’s filtering units are under pressure ^[2].

Transitioning into Adulthood

MPI-CDG is a lifelong condition, and the goals of care shift as a child grows. In adulthood, the risk of cirrhosis (advanced liver scarring) remains a possibility, even for those who were well-managed as children ^[7]. One documented case showed that a patient who appeared stable developed significant liver complications later in life, emphasizing that “graduating” from pediatric care means moving to an adult specialist who understands metabolic diseases, not stopping surveillance ^[7][8].

Maintaining a consistent relationship with a hepatologist (liver specialist) and a metabolic geneticist is the best way to ensure that any “silent” changes are caught early, allowing for adjustments in treatment or closer monitoring that keeps your child—and eventually the adult they become—safe and healthy ^[9][2]. Families and patients should not arrange repeated imaging or alter treatments independently, but rather rely on their care team.